Is antibody-mediated rejection in kidney transplant recipients a risk factor for developing cytomegalovirus or BK virus infection? Results from a case-control study.

Autor: Los-Arcos I; Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain; Departament of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain., Len O; Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain; Departament of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. Electronic address: oscar.len@vhir.org., Perello M; Nephrology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Torres IB; Nephrology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Codina G; Microbiology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Esperalba J; Microbiology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Sellarés J; Nephrology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Moreso F; Nephrology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Seron D; Nephrology Department, Vall d'Hebron University Hospital, Barcelona, Spain., Gavaldà J; Infectious Diseases Department, Vall d'Hebron University Hospital, Barcelona, Spain; Departament of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
Jazyk: angličtina
Zdroj: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology [J Clin Virol] 2019 Jan; Vol. 110, pp. 45-50. Date of Electronic Publication: 2018 Dec 01.
DOI: 10.1016/j.jcv.2018.11.010
Abstrakt: Background: Data are scarce on cytomegalovirus (CMV) and BK virus (BKV) infection after antibody-mediated rejection (ABMR).
Objectives: We hypothesized that the immunological response in patients with ABMR or the immune modulation associated with its treatment could predispose to CMV and BKV infection. Our objective was to investigate this hypothesis.
Study Design: We conducted a single-center, matched case-control study (1:2 ratio) to analyze CMV and BKV replication during the first year after the ABMR diagnosis in kidney transplant recipients. Adult recipients with a histopathological diagnosis of ABMR between 2007-2015 were included as cases. Controls were kidney recipients who underwent transplantation immediately before and after the index case.
Results: Fifty-eight patients diagnosed with ABMR (33 chronic active ABMR and 25 acute ABMR), with their matched controls (116) were included. Forty-four cases received treatment for ABMR, including plasmapheresis (41), immunoglobulins (40), and rituximab (31). Within 1 year after ABMR, cases showed CMV replication more often than controls (9/58, 15.5% vs 7/116, 6%, OR = 4.21, CI 1.10-16.16, p = 0.04). Over the study period, CMV PCR determinations were requested more frequently in cases than controls (46/58, 79.3% vs 63/116, 54.3%, OR = 4.58, CI 1.92-10.9, p = 0.001). On multivariate analysis adjusted for CMV PCR determinations, retransplantation, antithymocyte globulin treatment and methylprednisolone treatment for acute rejection, CMV replication remained more common in cases than in controls (OR = 2.41, CI 0.49-11.73, p = 0.28). There were no differences in BKV replication in either urine or blood.
Conclusions: ABMR may be a risk factor for CMV but not for BKV replication in kidney transplant recipients.
(Copyright © 2018 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: